Biotech: Interest ‘in vaccine stocks will probably wane,’ strategist says

Michael Yee, Managing Director at Jefferies, discusses Adagio and its treatment for COVID-19 as well as the outlook for Moderna in 2022 on Yahoo Finance Live.

相關影片推薦